SCHEMBL185322

SCHEMBL185322

Cc1ncc(C(=O)NC2(C(=O)O)CC2)cn1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMYD3 Q9H7B4 1/20 0.40
GPR132 Q9UNW8 2/20 0.38
HDAC6 Q9UBN7 10/20 0.37
HDAC1 Q13547 9/20 0.37
HDAC3 O15379 8/20 0.37
HDAC2 Q92769 8/20 0.37
PYGL P06737 1/20 0.36
HDAC4 P56524 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35
HDAC10 Q969S8 1/20 0.35
HDAC11 Q96DB2 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC9 Q9UKV0 1/20 0.35
HDAC5 Q9UQL6 1/20 0.35
BDKRB1 P46663 1/20 0.35
CXCR5 P32302 1/20 0.34
HCAR3 P49019 1/20 0.34
CTSL P07711 1/20 0.34
SPHK1 Q9NYA1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2808488 0.84 VNN1 (0.39) SMYD3HDAC6HDAC1HDAC3HDAC2
SCHEMBL2808491 0.84 VNN1 (0.39) SMYD3HDAC6HDAC1HDAC3HDAC2
SCHEMBL13128942 0.84 HDAC6 (0.41) GPR132HDAC6HDAC1HDAC3HDAC2
SCHEMBL13128941 0.83 GPR132 (0.38) GPR132HDAC6HDAC1HDAC3HDAC2
SCHEMBL21657030 0.80 HCAR3 (0.43) GPR132HDAC6HDAC1HDAC3HDAC2
SCHEMBL185415 0.79 BDKRB1 (0.47) GPR132PYGLBDKRB1CTSL
SCHEMBL5354663 0.73 GPR132 (0.43) GPR132HDAC6HDAC1HDAC3HDAC2
SCHEMBL20254518 0.73 RAB9A (0.43) PYGL
SCHEMBL1740329 0.73 CTSL (0.53) HDAC6HDAC1HDAC3HDAC2HDAC7
SCHEMBL198340 0.72 GPR132 (0.36) GPR132HDAC6PYGL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130131075-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-23 US disclosed
US-20130131075-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-23 US disclosed
EP-2401256-B1 Compounds as bradykinin B1 antagonists BOEHRINGER INGELHEIM INT (DE) 2013-04-17 EP disclosed
EP-2401256-B1 Compounds as bradykinin B1 antagonists BOEHRINGER INGELHEIM INT (DE) 2013-04-17 EP disclosed
EP-2401256-A1 COMPOUNDS AS BRADYKININ B1 ANTAGONISTS Boehringer Ingelheim International GmbH (DE) 2012-01-04 EP disclosed
US-20100240669-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 US disclosed
US-20100240669-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 US disclosed
US-20100240669-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 US disclosed
WO-2010097372-A1 COMPOUNDS AS BRADYKININ B1 ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131075-A1 NEW COMPOUNDS ADORA1, H1-10, P2RY11 SMYD3 3983/4885GPR132 864/4885HDAC6 1465/4885
US-20100240669-A1 NEW COMPOUNDS ADORA1, H1-10, P2RY11 SMYD3 3983/4885GPR132 864/4885HDAC6 1465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.